Cite
HARVARD Citation
Reardon, D. et al. (2018). Phase 2 and biomarker study of trebananib, an angiopoietin‐blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. Cancer. 124 (7), pp. 1438-1448. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Reardon, D. et al. (2018). Phase 2 and biomarker study of trebananib, an angiopoietin‐blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. Cancer. 124 (7), pp. 1438-1448. [Online].